Ulvovaginal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ulvovaginal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ulvovaginal Today - Breaking & Trending Today

Drugmaker pulls 17K antifungal pills in Class I recall

Scynexis is recalling 17,376 cartons of Brexafemme (ibrexafungerp) tablets due to a potential cross-contamination risk. ....

New Jersey , United States , Cross Contamination ,

GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with. | March 30, 2023 ....

United States , United Kingdom General , United Kingdom , New York , City Of , Jeff Mclaughlin , Luke Miels , James Dodwell , David Angulo , Dan Smith , Tim Foley , Camilla Campbell , Lyndsay Meyer , Irina Koffler , Nick Stone , Josh Williams , Vulvovaginal Candidiasis , Mick Readey , Debbie Etchison , Kathleen Quinn , Steph Mountifield , Spero Therapeutics Inc , Exchange Commission , Globenewswire Inc , Drug Administration , Scynexis Inc ,

GSK to exclusively license novel oral antifungal

GSK is set to gain exclusive rights to first-in-class oral antifungal Brexafemme for vulvovaginal candidiasis from SCYNEXIS. The exclusive licence agreement will enable GSK to commercialise. | March 30, 2023 ....

Luke Miels , Drug Administration , Russell Publishing , World Health Organization , Chief Commercial Officer , Health Organization , European Pharmaceutical , Russell Publishing Limited , Nc Stock Exchange , Press Release , O Scyx Us8112922005 ,